Carcinoma, Neuroendocrine - 25 Studies Found Estado Estudiar Not yet recruiting Nombre del estudio: Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic (GEP) Neuroendocrine Carcinoma (NEC, WHO Grade 3) as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes Condición: Neuroendocrine Carcinoma, Grade 3 Fecha: 2017-05-08 Intervenciones: Drug: Avelumab Avelumab 10 mg/kg i.v. every 2 weeks (Q2W) Completed Nombre del estudio: S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer Condición: Neuroendocrine Carcinoma of the Skin Fecha: 1999-11-01 Intervenciones: Drug: CMF regimen Drug: cyclophosphamide Active, not recruiting Nombre del estudio: An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours Condición: Fecha: 2024-05-19 Completed Nombre del estudio: Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers Condición: Fecha: 2024-05-19 Active, not recruiting Nombre del estudio: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Condición: Fecha: 2024-05-19 <<< Previous